Economic evaluation of personalized vs. standard dosing of 5-fluorouracil in first-line chemotherapy for metastatic colorectal cancer in Australia
CONCLUSIONS: PK dose management of 5-FU-based chemotherapy in mCRC patients appears to be a cost-saving strategy in Australia. However, our model estimates are drawn from limited, low-quality evidence. Further evidence from randomized controlled trials (RCTs), directly comparing PK-based to BSA-based dosing across a variety of current regimens, is needed to address our model's uncertainties.PMID:38346317 | DOI:10.1111/bcp.16013
Source: Clinical Colorectal Cancer - Category: Cancer & Oncology Authors: Daniel Erku Jennifer H Martin Michael Michael Peter Galettis Paul Scuffham Source Type: research
More News: Australia Health | Cancer | Cancer & Oncology | Chemotherapy | Colorectal Cancer | Healthcare Costs | Study | Toxicology